MEDVi Pros and Cons

Pros

• Unusually wide menu: injections and tablets for both semaglutide and tirzepatide
• Tablet tracks give needle-averse patients a real GLP-1 path
• Cash-pay model with a discounted first month and no insurance gatekeeping
• Round-the-clock access to the clinical team for questions and dose issues

Cons

• Refill pricing jumps well above the first-month rate — budget on month two, not month one
• Affordable tracks are compounded medication, not FDA-approved branded products
• The brand-name option carries a four-figure monthly price when it is available at all

MEDVi Highlights

• Both GLP-1 active ingredients in two delivery formats — the widest format choice in our weight-loss chart
• Advertised first month from $179 on the semaglutide injection track
• Licensed-provider review decides eligibility before any prescription ships
• Home delivery with instructions included; refills run through the platform
• For context on what GLP-1s achieve: trial averages ran 14.9% (semaglutide, STEP 1) to 20.9% (tirzepatide top dose, SURMOUNT-1) of body weight — alongside lifestyle intervention, never guaranteed individually

MEDVi Weight-Loss Treatment Plans

The catalog is the differentiator here. Where most cash-pay programs offer one or two compounded injection tracks, MEDVi runs five:

• Compounded semaglutide injections — the entry-price track, same active ingredient class as branded semaglutide products.
• Compounded tirzepatide injections — the dual GLP-1/GIP ingredient, at a higher monthly rate.
• Compounded semaglutide tablets — an oral route for patients who will not do weekly injections.
• Compounded tirzepatide tablets — the same trade-off in tablet form.
• Brand-name Ozempic® injections — subject to availability and priced accordingly.

One honesty note on the tablets: the landmark trial evidence for these ingredients comes from the injectable forms. Compounded tablets are a convenience adaptation, so discuss expectations for the oral route candidly with the prescribing clinician.

How MEDVi Works

1. Online Evaluation
   A health intake reviewed by licensed clinicians decides whether GLP-1 treatment fits you. Disclose everything — pregnancy plans, thyroid cancer history, current medications — because the screen is only as good as your answers.
2. Prescription Decision
   Approval pairs you with a specific medication and format from the five-track menu; declines happen when the medical picture warrants them.
3. Delivery and Refills
   Medication ships home with instructions, and the refill cycle runs through the platform with clinical support available around the clock.

MEDVi Pricing

The structure is a discounted first month followed by standard refill pricing. The advertised first month covers the doctor's review, plan, and initial prescription; refills on the semaglutide injection track then run around $299 per month, with specialist access bundled in. Advertised starting points by track:

• Semaglutide injections: from $179 (first month)
• Semaglutide tablets: from $249
• Tirzepatide injections: from $279
• Tirzepatide tablets: from $279
• Brand-name Ozempic®: from $1,999/month, availability permitting

Do the twelve-month math on refill pricing, not the intro rate — that is the number to compare against other programs in our chart. Prices shift with market conditions, so confirm current figures on MEDVi's site before enrolling.

The Bottom Line

MEDVi earns its chart position on menu breadth: it is the program to shortlist if you want format flexibility — especially tablets instead of injections — from a single cash-pay provider. The discipline it asks of you is financial: anchor your decision on refill pricing rather than the first-month rate, confirm the compounding pharmacy details, and have the oral-route expectations conversation with the clinician before choosing tablets over the trial-proven injectable forms.

Not ready to commit?

Find the weight loss product you need at a great price with side-by-side comparisons.
Best weight loss treatments

Want to compare more?
Back to company reviews